Shire reiterated at sector perform by RBC

RBC Capital Markets analyst Douglas Miehm reiterated Shire Pharmaceuticals at sector perform, above average risk. As a result of the company's settlement with Barr Laboratories in connection with generic Adderall, Barr's launch is delayed until 2009. The launch of NRP104 is now the focus for maintaining market share, according to the analyst. Delaying generic competition should positively impact Shire's revenue in 2008 and 2009. Shares of the Basingstoke, England-based pharmaceutical company were down 82 cents, or 1.62%, at $49.89 on volume of 1,349,730 shares versus the three-month running average of 628,548 shares. (Nasdaq: SHPGY)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.